Session Abstract – PMWC 2022 Silicon Valley

The PMWC 2021 Genomic Profiling Showcase will provide a 15 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.

Confirmed Presenting Companies:

 Session Chair Profile

M.D., Chief Medical Officer, Agendia

Dr. William Audeh is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles, where he continues to be a member of the Medical Staff. He became Chief Medical Officer of Agendia, a molecular diagnostics company specializing in breast cancer genomics, in May of 2016. Prior to joining Agendia, in addition to his clinical practice, he served as Director of the Cedars-Sinai Cancer Center, Clinical Chief of the Division of Hematology/Oncology, and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh was also a faculty member in the Breast Surgery and Surgical Oncology Fellowships at Cedars-Sinai and was Associate Clinical Professor of Medicine at the UCLA School of Medicine. Dr Audeh obtained his MD degree for the University of Iowa, MS in Genetics from University of Minnesota, and Internal Medicine and Oncology training at Stanford University.

Genomic Profiling Showcase:

From day one, Agendia was founded on the belief we could improve the quality of life for cancer patients everywhere. Today, our genomic tests are achieving this goal with a broad and growing global customer base, including many major hospitals and clinical institutions.

 Speaker Profile

CEO, Scipher Medicine

Alif is a pioneer in integrating network science with molecular data to match individual patients with the most effective therapies. Alif and his team have spent the last decade pioneering a network medicine platform – a powerful tool that has the potential to predict patient response to targeted therapies, develop precision diagnostics and repurpose previously approved drugs. A Swedish national with a perspective on global healthcare systems, Alif has led cross-disciplinary teams throughout Asia, Europe, and the Americas - raising over $225M in venture and private equity capital. Alif is an experienced speaker and writer on healthcare topics and was recently featured on The Bio Report podcast (“Bringing Precision Medicine to Autoimmune Disease”), at the BIO International Convention (“Precision Medicine Outside Oncology: One Size Does Not Fit All),” and on Morning Consult (“Addressing Healthcare’s Largest Hidden Cost: Drug Nonresponse”).

Genomic Profiling Showcase:
Scipher Medicine

Scipher Medicine is committed to transforming the way healthcare prioritizes drugs for patients. Our first product, PrismRA, is a first-of-its-kind blood test that can predict which patients with rheumatoid arthritis are less likely to respond to the world's best-selling drug class: TNF inhibitors.

Bringing Precision Medicine To Autoimmune Disease
In rheumatoid arthritis, only 1 in 3 patients respond to the top biologic therapies. Scipher Medicine’s PrismRA test identifies patients who are less likely to respond to TNFi therapies, allowing patients to optimize drug class selection prior to treatment.

 Speaker Profile

Ph.D., CEO, Ciscovery Bio

Joonyul Kim (CEO) has many years of managing experience as a founder CEO in his first startup company. While at the company, he secured multiple non-dilutive funds including NSF STTR Phase I and research contracts with the private drug discovery companies. He got a Ph.D. from Michigan State Univ. in the field of molecular genetics and had postdoctoral training in the area of bioanalytical chemistry before starting his entrepreneurial career.

Genomic Profiling Showcase:
Ciscovery Bio

We are a genomics company that enables cis-regulatory modules (CRMs) such as enhancers and promoters for drug development, precision medicine and biotechnology. Our CRM-based approach maps the drug-genome relationship for the prediction of drug toxicity and patients' drug response.

Mapping of the Drug-genome Relationship
Under various drug treatment conditions, we monitored the activities of >100,000 promoters/enhancers to comprehensively detect drug-induced changes in regulatory states within cells. This approach was able to map the drug-genome relationship, a foundation for precision medicine.

 Speaker Profile

Ph.D., M.D., Chief Medical Officer, Beverly Hills Institute for Precision Medicine

Dr. Stanford’s clinical practice is focused on providing consultative services to primary care providers for the purposes of the integration of precision medicine into primary care plans. This approach is novel from its comprehensive nature and practical real-world implementation. Dr. Stanford began his career as a Mechanical/Aerospace Engineer at Texas Instruments in 1982. In 1991, he pivoted into biomedical science and completed the physician-scientist training program (MD/PhD) at UCLA in 1998 and internal medicine residency at UCLA in 2001. Dr. Stanford was one of the pioneers in the field of hospital medicine. In 2002, he founded and led a 25-physician group of private practice hospitalists at Cedars-Sinai Medical Center in Los Angeles and was elected by his peers to be Clinical Chief of General Internal Medicine. He completed Professional Certification in Genetics and Genomics through Stanford University in 2018 and subsequently founded the Beverly Hills Institute for Precision Medicine.

Genomic Profiling Showcase:
Beverly Hills Institute for Precision Medicine

BHIPM provides comprehensive consultative services to primary care providers and their patients for the purposes of integrating precision medicine recommendations into primary care plans.

Precision Medicine Consultation in Primary Care
This presentation provides an overview of the consultative approach taken by BHIPM in using whole genome sequencing and analysis, alongside the patient's comprehensive past medical history, extended family medical history and recent biochemical studies to inform personalized primary care plans.